OncoMatch/Clinical Trials/NCT04868162
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Is NCT04868162 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including MRG003 and MRG003+HX008 for recurrent or metastatic squamous cell carcinoma of head and neck.
Treatment: MRG003 · MRG003+HX008 — The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — recurrent or metastatic
Failed prior platinum and/or anti-PD-1 treatment (Part A); failed or intolerant to at least one prior line of standard therapy (platinum-based regimen) (Part B)
Cannot have received: MMAE/MMAF antibody-drug conjugate
Prior anti-tumor therapy with MMAE/MMAF ADCs
Lab requirements
Blood counts
Organ functions and coagulation function must meet the basic requirements.
Kidney function
Organ functions and coagulation function must meet the basic requirements.
Liver function
Organ functions and coagulation function must meet the basic requirements.
Organ functions and coagulation function must meet the basic requirements.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04868162 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MMAE/MMAF antibody-drug conjugate disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages